Uwe Weisner

April 12, 2021

As General Manager Corporate Intellectual Property at Volkswagen AG in Wolfsburg, Germany, Uwe is responsible for filing, prosecuting, licensing and enforcing Volkswagen’s Patents, Trademarks, Design Rights, Internet-Domains and defending against third party IP claims. In addition, he is responsible for standardization. Prior, Uwe served more than 15 years as a Patent Manager for Volkswagen AG and Audi AG, also located in Germany. Further functions: Chairman of the IP Committee of VDA (German Association of Automotive Industry), Board Member of the IP Committee of BDI (Association of German Industries) and Board Member of VPP (Association of Industry Patent Professionals in Germany). From 2010 to 2017 Lecturer at the Technical University of Braunschweig for “Business Practice of Intellectual Property.”

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor